

1 Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19
2 vaccine in adults: data from a randomised, double-blind, placebo-
3 controlled, single-dose, phase 3 trial in Russia

4
5 Dmitry Lioznov^{1,2}, Irina Amosova¹, Savely A. Sheetikov³, Ksenia V. Zornikova³, Yana Serdyuk³,
6 Grigory A. Efimov³, Mikhail Tsyferov⁴, Mikhail Khmelevskii⁴, Andrei Afanasiev⁴, Nadezhda
7 Khomyakova⁴, Dmitry Zubkov⁴, Anton Tikhonov⁴, Tao Zhu⁵, Luis Barreto⁵, Vitalina Dzutseva^{4,6*}

8
9 ¹ Smorodintsev Research Institute of Influenza, St Petersburg, Russia

10 ² Department of Infectious Diseases and Epidemiology, First Pavlov State Medical University, St.
11 Petersburg, Russia

12 ³ National Research Center for Hematology, Moscow, Russia

13 ⁴ NPO Petrovax Pharm LLC, Moscow, Russia

14 ⁵ CanSino Biologics Inc., Tianjin, China

15 ⁶ Novosibirsk State University, Medical School, Novosibirsk, Russia

16 * Corresponding author

17 E-mail: DzutsevaVV@petrovax.ru (VD)

18

19 **Short title:** COVID-19 vaccination Ad5-nCoV in Russian adults

20 **ABSTRACT**

21 **Background:** To determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose
22 of recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5×10^{10} viral particles
23 per 0.5 mL dose), we conducted a single-dose, randomised, double-blind, placebo-controlled, parallel
24 group (3:1 Ad5-nCoV:placebo), phase 3 trial (Prometheus).

25 **Methods:** From 11-September-2020 to 05-May-2021, across six sites in the Russian Federation, 496
26 participants were injected with either placebo or Ad5-nCoV expressing the full-length spike (S)
27 protein from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 **Results:** Seroconversion (the primary endpoint) rates of 78.5% (95% CI: 73.9; 82.6) against receptor
29 binding domain (RBD), 90.6% (95% CI: 87.2; 93.4) against S protein and 59% (95% CI: 53.3; 64.6)
30 against neutralising SARS-CoV2 antibodies 28 days post-vaccination. Geometric mean titres
31 (GMTs) were also elevated for antibodies against the RBD (405.32 [95% CI: 361.58; 454.46]) and S
32 protein (678.86 [95% CI: 607.44; 754.40]) compared to the GMT of neutralising antibodies against
33 SARS-CoV-2 (16.73 [95% CI: 15.36; 18.22]). Using an IFN- γ ELISpot assay after stimulating the
34 cells with full-length S protein we showed that the Ad5-nCoV vaccine induced the most robust
35 cellular immune response on Days 14 and 28. Up to Day 28, the primary and all secondary endpoints
36 of the Ad5-nCoV vaccine were statistically superior to the placebo ($p < 0.001$). Systemic reactions
37 were reported in 113 of 496 (22.8%) participants (Ad5-nCoV, 26.9%; Placebo, 10.5%), and local
38 reactions were reported in 108 (21.8%) participants (Ad5-nCoV, 28.5%; Placebo, 1.6%). These were
39 generally mild and resolved within 7 days after vaccination. Of the six serious adverse events
40 reported, none of the events were vaccine related. There were no deaths or premature withdrawals.

41 **Conclusion:** A single-dose of Ad5-nCoV vaccine induced a marked specific humoral and cellular
42 immune response with a favourable safety profile.

43 **Trial Registration:** ClinicalTrials.gov: NCT04540419

44 INTRODUCTION

45 The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2
46 (SARS-CoV-2) has resulted in morbidity and mortality unseen since the Spanish flu outbreak more
47 than a century ago [1]. Quarantine measures, a traditional public health method of infection control,
48 have been only partially effective in the face of this highly transmissible virus [2]. Vaccination has
49 the potential to reduce disease severity and transmission but requires expedited development and
50 global administration. In response to this enormous task, many potential vaccine candidates are in
51 development, with several now approved for full or limited use being actively administered [3–6]. A
52 range of technologies have been used in the development of SARS-CoV-2 vaccines, including
53 replicating or non-replicating viral vectors, inactivated viruses and mRNA, DNA or autologous cell-
54 based vaccines. It is not currently known which approach provides the most effective immunity for
55 different recipient risk groups with an acceptable safety profile, all at acceptable levels of cost with
56 ease of manufacturing and distribution [7].

57 A candidate COVID-19 vaccine that initially showed a capacity to induce a significant antibody and
58 cellular immune response is the adenovirus type 5 (Ad5)-nCoV vaccine developed by CanSino
59 Biologics Inc., Tianjin, and the Beijing Institute of Biotechnology, People’s Republic of China. It
60 consists of a replication-defective Ad5 vector expressing the SARS-CoV-2 spike (S) protein,
61 including its receptor-binding domain (RBD). This protein serves as the main antigen in SARS-CoV-
62 2 vaccines [8]. The Ad5-nCoV vaccine was one of the first to enter phase 1 and 2 clinical trials in
63 China, 2 months after the identification of the virus genotype and the results showed the vaccine to
64 be safe and immunogenic after a single dose [9, 10]. Its potential advantages are single-dose
65 immunization and its proven technology, both of which were used previously for the Ebola vaccine
66 (Ad5-EBOV), and its stability that permits it to be stored in a standard refrigerator at 2–8°C,
67 enabling the ease of worldwide distribution.

68 A collaborative development project between CanSino Biologics and the Russian pharmaceutical
69 company NPO Petrovax Pharm LLC provided the basis for a new phase 3 study, Prometheus Rus.
70 This multicentre, randomised, double-blind, placebo-controlled clinical trial examines the
71 immunogenicity, reactogenicity, efficacy and safety of the Ad5-nCoV COVID-19 vaccine compared
72 with placebo, in a mostly white, Russian population. The study population was recruited at centres in
73 the western part of the Russian federation (Moscow, St. Petersburg and Yaroslavl) and therefore
74 provides the first clinical data available for Ad5-nCoV in a white European population; previously
75 published data were based on the phase 1 and 2 clinical trials conducted in China. We present the
76 final analysis of the 496 participants in this phase 3 trial.

77 **MATERIALS AND METHODS**

78 The protocol for this trial and supporting CONSORT checklist are available as supporting
79 information; see S1 Protocol and S1 Checklist, respectively.

80 **Ethical Conduct of the Study**

81 The study proceeded in accordance with the principles of the Declaration of Helsinki and Good
82 Clinical Practice. The trial protocol was reviewed and approved by the Independent Ethics
83 Committees of the involved sites and the Ethics Council of the Ministry of Health of the Russian
84 Federation. The study design and methodology have been developed in line with the FDA [11], EMA
85 [12] and EAEU [13] guidelines, as well as the regulatory documents of the Russian Federation [14].
86 The trial is registered with ClinicalTrials.gov, NCT04540419 [15].

87 To be included, participants needed to be able to understand the content of the informed consent
88 documents and be willing to sign the informed consent form. Written informed consent was obtained
89 from each participant before eligibility screening.

90 **Study Design and Participants**

91 Prometheus is a multicentre, randomised, double-blind, placebo-controlled, clinical trial being
92 conducted in six centres in the Russian Federation. The study seeks to evaluate the immunogenicity,
93 efficacy, reactogenicity and safety of a single dose of the Ad5-nCoV COVID-19 vaccine compared
94 with placebo in adults up to 6 months after vaccination. Competitive recruitment of the planned
95 sample size of 500 eligible participants in six centres was completed in November 2020 and follow-
96 up observations were completed on 05-May-2021. A planned interim analysis of data collected in
97 200 participants up to 28 days after a single injection of Ad5-nCoV or placebo was completed on

98 21-December-2020. Herein, we present the results of final analysis of data collected in 496
99 participants up to 6 months after a single injection of Ad5-nCoV or placebo.

100 Participation was sought through online recruitment advertising and patient databases of the trial
101 sites. All participants underwent detailed screening 1–10 days before vaccination with Ad5-nCoV or
102 placebo (Day 0). Screening included the detection of SARS-CoV-2 RNA using real-time polymerase
103 chain reaction (PCR) via a swab, and SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin
104 G (IgG) antibody testing to ensure negative results, as well as testing for human immunodeficiency
105 virus (HIV), syphilis, hepatitis B and hepatitis C viruses via blood serum. A detailed medical history
106 for each participant was taken and records included if the participant experienced any COVID-19
107 symptoms and if the participant was in close contact with people suspected or proven to have SARS-
108 CoV-2 infection. Participants underwent physical examination (including a neurological
109 examination, vital signs, and body temperature), haematological, biochemical and coagulation
110 testing, urinalysis, electrocardiogram, and when applicable, pregnancy testing as pregnancy (and
111 breastfeeding) was an exclusion criterion.

112 Men and women aged 18–85 years with a body mass index (BMI) between 18.5 and 30.0 kg/m² were
113 selected to participate if they had no indication of a current or previous SARS-CoV-2 infection (e.g.,
114 respiratory infection in last 14 days, axillary temperature ≥ 37.0 °C) or close contact with a suspected
115 or confirmed case of SARS-CoV-2 infection. Participants were considered to be eligible if they were
116 in general good health as established by medical history and screening. Those with a range of chronic
117 illnesses, including mental disorders, a history of allergies, recipients of concurrent medication, those
118 with addictions, and those for whom there were concerns over adherence to study protocol were also
119 excluded.

120 **Randomisation and Masking**

121 The investigational vaccine, Ad5-nCoV, and the placebo were provided by NPO Petrovax Pharm
122 LLC (Moscow, Russia). Both vaccine and placebo were developed by CanSino Biologics Inc.
123 (Tianjin, China) and the Beijing Institute of Biotechnology (Beijing, China). The vaccine was
124 administered with the optimal dose of 5×10^{10} viral particles per 0.5 mL dose, as determined in a
125 previous study [9, 10]; placebo contained vaccine excipients only. The appearance of Ad5-nCoV and
126 placebo syringes and packaging was identical.

127 Eligible participants were randomly allocated to the Ad5-nCoV group or the Placebo group, in a 3:1
128 ratio, by an independent statistician using a validated system including a pseudorandom number
129 generator with a seed value; allocation used block randomisation and stratification by study site.
130 Neither the investigators nor participants were aware of the group assignment. Investigators were
131 trained to use the centralised interactive web response system that was used for randomisation.
132 Randomisation codes were kept by authorised personnel from the responsible contracted
133 organisation.

134 **Procedures**

135 A single dose (0.5 mL) of Ad5-nCoV or placebo was administered by intramuscular (IM) injection to
136 the upper arm on Day 0. Participants were requested to remain at the site for 2 h after vaccination for
137 study staff to monitor for any systemic or local reactions to vaccination. Following the administration
138 of the vaccine or placebo, participants attended clinic visits on Day 2, Day 7, Day 14, Day 28 and
139 after Month 6. Between Day 28 and Month 6 there were phone calls at Months 2, 3, 4 and 5.

140 Determination of serum antibodies against the S protein and RBD of SARS-CoV-2 and the presence
141 of neutralising antibodies against SARS-CoV-2 were conducted on Day 0, Day 14, Day 28 and after

142 Month 6; neutralising antibodies against Ad5 were assessed on Day 0, Day 28 and after Month 6.
143 Immunoglobulin G antibodies to the S protein and RBD were determined using indirect enzyme-
144 linked immunosorbent assay kits that involved incubation of serially diluted serum samples with the
145 recombinant antigen (either RBD [SARS-CoV-2-IgG-EIA; XEMA Co. Ltd] or S protein [SARS-
146 CoV-2-IgG-EIA-BEST; Vector-Best]) immobilised to the surface of a 96-well plate. The assays were
147 performed according to the manufacturer's instructions. Horseradish-peroxidase conjugated mouse
148 monoclonal anti-human IgG antibody was used to detect antibodies, visualised with
149 tetramethylbenzidine substrate solution. The detection limit for antibodies against the S protein and
150 RBD of SARS-CoV-2 was 1:100.

151 Anti-coronavirus neutralising antibodies were determined with a microneutralisation assay in which
152 Vero cell (#CCL-81, American Type Culture Collection) monolayers were incubated in 96-well
153 plates with 2-fold serial dilutions (1:10 to 1:1280) of participant serum. Recently thawed and diluted
154 SARS-CoV-2 virus ([GISAID HCoV-19/st_petersburg-3524S/2020] was obtained from the clinical
155 material collection at Smorodintsev Research Institute of Influenza, St. Petersburg, Russia) was
156 added to the wells, and plates were incubated for 1 h at $37\pm 0.5^{\circ}\text{C}$ in a humidified incubator. Medium
157 was removed from wells, replaced with a mixture of the most highly diluted (1:1280) serum and
158 virus, and plates were incubated at $37\pm 0.5^{\circ}\text{C}$ and 5% CO_2 for 4 days. Anti-adenovirus neutralising
159 antibodies were also determined using microneutralisation assay; A549 cell monolayers were
160 incubated in 96-well plates with serial dilutions (1:10 to 1:1280) of participant serum and working
161 dilutions of Ad5 (Adenovir; Smorodintsev Research Institute of Influenza). Plates were incubated for
162 2 h at $36\pm 0.5^{\circ}\text{C}$ and 5% CO_2 . Medium was removed from wells, replaced with a mixture of diluted
163 serums and working virus dilution, and plates were incubated at $36\pm 0.5^{\circ}\text{C}$ and 5% CO_2 for 72 h. For
164 both microneutralisation assays, results were assessed by visual inspection of cytopathic effects.
165 Serum titres were determined as the maximum dilution at which complete inhibition of viral

166 reproduction was detected as the result of interaction between virus and specific antibodies; the
167 detection limit was 1:10. Antibody titres undetectable in serum were assigned values of half of the
168 detection limits for calculation.

169 Sequence encoding Δ Furin variant of SARS-CoV-2 S protein (amino acids 1–1213) containing a C-
170 terminal Gly-Gly-6xHis tag was subcloned into the pMCAG-2T vector using the GeneArt Type IIs
171 Assembly Kit, *Bbs*I (Thermo Fisher Scientific), according to the manufacturer's instructions.
172 Recombinant SARS-CoV-2 S protein was expressed in Expi293F cells (Thermo Fisher Scientific) as
173 previously described [16]. Five days following transfection, cells were harvested via centrifugation
174 (15,600 x g), the supernatant was concentrated and diafiltered using the ÄKTATM flux tangential
175 flow filtration system (Cytiva) into buffer A (10 mM phosphate buffer, 2.7 mM KCl, 500 mM NaCl,
176 pH 8.0). The His-tagged S protein was further purified using Ni-NTA agarose resin (Qiagen),
177 washed with buffer A containing 30 mM imidazole and eluted in buffer A with 200 mM imidazole.
178 Using a Slide-A-Lyzer Dialysis Cassette (20K MWCO, Thermo Fisher Scientific), the eluate was
179 dialysed against PBS (10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl, pH 7.5) before use in
180 subsequent experiments.

181 To measure the cellular immune response from T cells (specifically CD8⁺ and CD4⁺ T cells),
182 peripheral blood mononuclear cells (PBMCs) from participants were isolated and tested as described
183 by Shomuradova et al. [16]. In brief, 30 mL of venous blood was collected from the participants and
184 centrifuged via a density gradient (Ficoll; PanEco) for 400 x g for 30 min to isolate PBMCs, which
185 were washed with PBS containing 2 mM EDTA. For the enzyme-linked immunospot (ELISpot)
186 assay, PBMCs (3 x 10⁵ cell/well) were plated into 96-well nitrocellulose plate that was pre-coated
187 with human IFN- γ capture antibody (ImmunoSpot kit Human IFN γ Single-Color ELISpot kit,
188 Cellular Technology Limited) in serum-free test medium (Cellular Technology Limited) containing 1
189 mM GlutaMAX (Gibco) in a final volume of 200 μ L/well as previously described [16]. To stimulate

190 the cells, cells were pulsed in duplicates with the S protein at a final concentration of 10 µg/mL or
191 with a pool of overlapping peptides covering the human S protein (PepTivator SARS-CoV-2 Prot S
192 [Cat. No. 130-126-701; Miltenyi Biotec]) at a final concentration of 1 µM. Plates were incubated at
193 37°C in 5% CO₂ for 18 h, and then the assays were performed according to manufacturer's
194 instructions. Plates were washed twice with PBS, washed twice with PBS + 0.05% Tween-20, and
195 then incubated at room temperature with biotinylated anti-human IFN-γ detection antibody for 2 h.
196 Plates were then washed three times with PBS + 0.05% Tween-20, and then incubated at room
197 temperature with streptavidin-AP for 30 min. After at least two washes, the colorimetric reaction was
198 initiated by adding the substrate components for 15 min at room temperature. The reaction was
199 halted by gently rinsing the plate with distilled water. Spots were counted with the ImmunoSpot
200 Analyzer using the ImmunoSpot software (Cellular Technology Limited). Samples were designated
201 as positive for a T cell response when the mean number of spots in two replicas minus the number of
202 spots in the negative control was ≥10.

203 Evidence of local and general reactogenicity (frequency and nature of systemic and local
204 immunisation reactions on the day of vaccination and within 7 days after vaccination) was sought on
205 Day 0, Day 2 and Day 7. Adverse events (AEs) were monitored from the day of vaccination (Day 0)
206 onwards, during a scheduled phone call that evening, and at all subsequent clinic visits. A physical
207 examination, including neurologic examination, and vital signs, including body temperature, was
208 conducted at all visits (screening, Day 0, Day 2, Day 7, Day 14, Day 28 and Month 6). Participants
209 received telephone calls after 2, 3, 4 and 5 months, and were asked to answer questions to assess
210 safety and determine if they presented with signs of an acute respiratory infection due to COVID-19.
211 Haematology, clinical biochemistry, coagulation testing and urinalysis were conducted at screening,
212 day 2 and Day 28; electrocardiography was performed at screening and on day 2. Immunoglobulin E

213 (IgE) levels were assessed to determine any allergic effects of vaccine components at screening and
214 on Day 28.

215 **Outcomes**

216 The primary endpoint was the seroconversion rate, specifically the percentage of individuals with a
217 4-fold or higher increase in antibody titres to the RBD of the SARS-CoV-2 S protein, 28 days after
218 vaccination. Secondary endpoints included the assessment of four outcomes: 1) examining the
219 seroconversion rates in response to RBD, S protein and neutralising SARS-CoV-2 antibodies on Day
220 14, Day 28 (except for RBD) and at Month 6; 2) geometric mean titres (GMTs) of serum antibodies
221 against the RBD, S protein and neutralising antibodies against SARS-CoV-2 on Day 14, Day 28 and
222 Month 6 post-vaccination; 3) GMTs of neutralising antibodies against the Ad5 vector on Day 28 and
223 Month 6 post-vaccination; and 4) the cellular immune response as indicated by the secretion of IFN- γ
224 on Day 14, Day 28 and Month 6 post-vaccination.

225 Exploratory endpoints were the frequency of laboratory-confirmed COVID-19 cases, severe COVID-
226 19 cases, hospitalisations due to COVID-19 and COVID-19-related deaths (Day 14 to Month 6 post-
227 vaccination). The safety endpoints were reactogenicity (Day 0 to day 7), the frequency and nature of
228 AEs (Day 0 to the end of the study [Month 6 Visit]), and the results of physical and laboratory
229 examinations (i.e., haematological tests, urinalysis, serum IgE concentration).

230 Of note, two definitions were used to define seroconversion, one quantitative and one qualitative.

231 The primary and secondary endpoints used the quantitative definition: the proportion of participants
232 with at least a 4-fold increase in antibody titres against SARS-CoV-2 S protein and/or its RBD,
233 specifically. The qualitative analysis was defined as an antibody titre above the lower limit of
234 quantification (LLOQ) post-vaccination (if the baseline titre was below the LLOQ), or a 4-fold
235 increase over baseline post-vaccination (if the baseline titre was above the LLOQ).

236 **Statistical Methods**

237 Statistical analysis was performed using SPSS Statistics, Version 26.0 (IBM Corp.). Initially, as part
238 of the interim analysis and to ensure 90% power for the between-group comparison of the primary
239 variable, 180 subjects were to be included. This was based on the assumptions of a 20%
240 seroconversion rate in the Placebo group (based on quantitative analysis), superiority of the vaccine
241 group of $\geq 30\%$ (conservative assumption, odds ratio = 4), corrected two-sided significance level of
242 0.02616 (one-sided level of 0.01308) and the randomisation ratio of 3:1. Considering potential
243 dropouts from the study during the initial observation period of 28 days (10% of subjects), the total
244 number of randomised participants was increased to 200. To provide more detailed safety and
245 efficacy data (including age subgroups) and to descriptively present the frequency of confirmed
246 COVID-19 cases that occurred within 6 months post-vaccination (except for COVID-19 cases that
247 developed during the first 14 days after the vaccination), a sample size of 500 was selected.

248 An unblinded interim analysis was originally planned and conducted in this clinical trial when
249 obtaining partial information to evaluate the primary endpoint, gathered from the first 200
250 randomised volunteers and based on the results collected up to Day 28 (Visit 5), including the data
251 for those who left the trial before Visit 5. Subsequently, an alpha spending function (that is, an
252 increasing function of the proportion of the maximum sample size) of the Pocock type was employed
253 to adjust the level of significance due to the multiple comparisons of the primary variable in the
254 planned interim and final analysis sets. Analyses were performed with bilateral alpha levels of
255 0.02616 and 0.03039 on the interim and final analysis sets, respectively (with a total bilateral
256 significance level of 5%).

257 Variables representing the seroconversion rate (the proportion of participants with at least a 4-fold
258 increase in antibody titres) were tabulated by evaluation time-points and treatment groups, and two-

259 sided Clopper-Pearson 95% confidence intervals (CIs) presented. Comparative analysis of the
260 primary endpoint (seroconversion, quantitative definition) was performed using the Cochran-Mantel-
261 Haenszel test and the chi-squared test (or Fisher's exact test).

262 Antibody GMTs and neutralising antibody GMTs were presented and compared by evaluation time
263 points based on the calculated 95% CIs using two-way analysis of variance (ANOVA) following
264 logarithmic transformation. Mean log-transformed differences between the study groups (vaccine
265 and placebo) were evaluated with the corresponding 95% CI. The point estimates of the mean
266 differences and the corresponding CIs were back-transformed.

267 Geometric mean fold-increases in antibody and neutralising antibody titres for each treatment group
268 and each antibody GMT evaluation time point were assessed with the corresponding two-sided 95%
269 CIs following log-transformation, point estimation of the difference and CIs, and back-
270 transformation of obtained values. Between-group comparisons were performed using ANOVA
271 following the logarithmic transformation. Results from the ELISpot assay to assess differences in
272 cellular immunity were analysed using Mann-Whitney test with Bonferroni adjustment of p-values.

273 Statistical significance was accepted at $p < 0.05$. Results for immunogenicity analyses are presented
274 for the full analysis set ([FAS], which included all eligible participants who received a dose of
275 vaccine and provided at least one immunogenicity assessment result). Results for the per protocol set
276 ([PPS], which included members of the FAS who received a dose of vaccine according to the
277 randomisation and study scheme and provided data for immunogenicity assessment before and after
278 vaccination in line with the study scheme, did not receive a prohibited therapy, had no significant
279 protocol deviations that could have impacted efficacy assessment and did not develop COVID-19
280 within the first 14 days post-vaccination) were similar to those of the FAS and are therefore not
281 presented. Cellular immunity results were analysed in participants from the FAS that provided at

282 least one cellular immunity assessment result. Prophylactic efficacy results are presented for the PPS
283 (for efficacy analysis). The safety analysis set included all randomized volunteers who received a
284 dose of the vaccine.

285 **Patient and Public Involvement**

286 Participants were not directly involved in the development, implementation, or interpretation of this
287 study due to the requirement for a quick response to the rapidly-evolving coronavirus pandemic.

288 **Data Sharing**

289 The Authors commit to making the relevant anonymised participant level data available upon
290 reasonable request for 3 years following publication of this study. Requests should be directed to the
291 corresponding author.

292 **RESULTS**

293 Out of the 783 participants who were screened, this analysis included 500 eligible participants
294 intended for vaccination at six locations in the Russian Federation between 11 September 2020 and
295 11 November 2020. Of these, 374 participants were randomised to the Ad5-nCoV group and 126 to
296 the Placebo group (Fig. 1). The safety analysis set included 496 participants, the FAS for
297 immunogenicity analysis included 495 participants, and the PPS for efficacy analysis included 481
298 participants.

299 **Fig. 1.** Participant flow diagram. AE, adverse event; FAS, Full Analysis Set; PPS, Per-Protocol Set.

300 The mean age of participants was 41.2 years (range 18–79 years), with 300 (60.5%) participants aged
301 18–44 years, 161 (32.5%) aged 45–59 years, and 35 (7.1%) aged 60 years or older (Table 1). There
302 were more males (297 out of 496 [59.9%]) than females. The vast majority of the participants
303 (99.4%) were white race and 3 participants were Asian. Baseline characteristics were largely similar
304 across groups.

305 **Table 1. Participant Demographics.**

	Ad5-nCoV N=372	Placebo N=124	Total N=496
Age (years[%])			
18–44 years	223 (59.9)	77 (62.1)	300 (60.5)
45–59 years	122 (32.8)	39 (31.5)	161(32.5)
≥60 years	27 (7.3)	8 (6.5)	35 (7.1)
Mean	41.2	41.0	41.2
Sex (n[%])			
Male	151 (40.6)	48 (38.7)	199 (40.1)
Female	221 (59.4)	76 (61.3)	297 (59.9)
Race (n[%])			
White	371 (99.7)	122 (98.4)	493 (99.4)
Asian	1 (0.3)	2 (1.6)	3 (0.6)
Country (n[%])			
Russia	372 (100%)	124 (100%)	496 (100%)
Body Mass Index (kg/m²)			
Mean	25.03	24.7	24.94
Minimum	18.6	18.6	18.5
Maximum	30.0	29.9	30.0
Underlying Disease (n[%])			
Yes	34 (22.8)	9 (18.0)	43 (21.6)
No	115 (77.2)	41 (82.0)	156 (78.4)
Prior Disease (n[%])			
Yes	176 (47.3)	56 (45.2)	232 (46.8)
No	93 (62.4)	36 (72.0)	129 (64.8)

306 **Immunogenicity and efficacy results**

307 Baseline antibody titres of the participants in the FAS (Ad5-nCoV; placebo) were similar for anti-

308 RBD antibodies (50.1; 50.0), anti-S protein (50.3; 50.3), neutralising anti-SARS-CoV-2 antibodies

309 (5.0; 5.0), as well as neutralising antibodies against the Ad5 vector (11.3; 8.8). Administration of the

310 Ad5-nCoV vaccine led to a marked increase in anti-RBD antibody response compared with placebo
311 across the FAS, with GMTs of 138.61 (95% CI: 125.60; 152.97) on Day 14 and 405.32 (95% CI:
312 361.58; 454.46) on Day 28; differences compared with placebo achieved statistical significance on
313 days 14 and 28 (both $p < 0.001$; Fig. 2). Six months following vaccination, antibodies levels in the
314 vaccinated group remained high with a mean GMT of 153.07 (95% CI: 133.08; 176.08).
315 Interestingly, a notable increase in anti-RBD antibodies at Month 6 was also observed in the Placebo
316 group, which could be attributed to an asymptomatic infection (GMT of 115.50 [95% CI: 88.84;
317 150.18], $p = 0.064$).

318 **Fig. 2.** Geometric mean titre (GMT) of serum antibodies against the RBD and SARS-CoV-2 S
319 protein on Day 0, Day 14, Day 28 and Month 6 after vaccination. The GMTs with 95% CI are shown
320 for serum antibodies against Ad5 (ADENOVAB), SARS-CoV-2 neutralising antibodies
321 (SAR2NAB), RBD (SAR2RBD) and S protein (SAR2S) (***, $p < 0.001$). Ad5, adenovirus type-5; CI,
322 confidence interval; RBD, receptor binding domain; S, spike; SARS-CoV-2, severe acute respiratory
323 syndrome coronavirus 2.

324 In the primary analysis on Day 28, 285 (78.5%, 95% CI: 73.9; 82.6) of 363 participants in the Ad5-
325 nCoV group showed seroconversion of RBD-specific antibodies compared with 7 (5.9%; 95% CI:
326 2.4, 11.7) of 119 participants in the Placebo group, which was indicative of a significant treatment
327 difference (Ad5-nCoV – placebo was 72.6% [95% CI: 65.7, 78.1; $p < 0.001$]). On Day 14, 152/359
328 (42.3%) participants from the Ad5-nCoV group showed seroconversion of RBD-specific antibodies
329 compared with the Placebo group ($p \leq 0.001$). However, at Month 6, 140/353 (39.7%) participants in
330 the Ad5-nCoV group showed a slight reduction in the seroconversion rate of RBD-specific
331 antibodies compared with the Placebo group (35/101 [34.7%]; $p = 0.354$).

332 The vaccine dose also induced a significant increase in anti-S protein antibody responses, with a
333 GMT of 288.60 on Day 14 (95% CI: 258.05; 322.78) compared with the Placebo group (51.49 [95%
334 CI: 42.34; 62.62; $p \leq 0.001$]); moreover, the significant increase in anti-S protein was also observed
335 on Day 28, with a GMT of 676.87 (95% CI: 607.44; 754.40) compared with the Placebo group
336 (61.31 [95% CI: 50.71; 74.11; $p \leq 0.001$]). This increasing trend in anti-S protein antibody responses
337 continued even at Month 6, with a GMT of 293.22 (95% CI: 252.12; 341.11) compared with the
338 Placebo group (145.85 [95% CI: 109.85; 193.64; $p \leq 0.001$]) (Fig. 2). Similarly, 239 (66.6%, 95% CI:
339 61.4; 71.4) of 359 participants had seroconverted with S protein-specific antibodies by Day 14
340 compared with 1 (0/8%, 95% CI: 0.0; 4.6) of 118 the Placebo group ($p \leq 0.001$). Additionally, 329
341 (90.6%, 95% CI: 87.2; 93.4) of 363 participants also had significantly elevated levels of
342 seroconversion with S protein-specific antibodies by Day 28 compared with the Placebo group
343 (6.7% [95% CI: 2.9; 12.8; $p \leq 0.001$]). Treatment difference on Day 28 was 65.9% (95% CI: 59.6;
344 71.3) compared with the Placebo group ($p < 0.001$). At Month 6, 222 (62.9% (95% CI: 57.6; 67.9) of
345 353 participants had seroconverted with S protein-specific antibodies compared to the Placebo group
346 (41 [40.6%] of 101 participants; $p \leq 0.001$).

347 Administration of the Ad5-nCoV vaccine induced significant greater neutralising antibody responses
348 to SARS-CoV-2 than placebo ($p < 0.001$), with GMTs of 8.78 on Day 14 (95% CI: 8.19; 9.41) and
349 16.73 on Day 28 (95% CI: 15.36; 18.22). At Month 6, significantly greater neutralising antibody
350 responses to SARS-CoV-2 were still present, with a GMT of 19.50 (95% CI: 16.97; 22.41) compared
351 with a GMT of 8.94 (95% CI: 6.63; 12.04) in the Placebo group ($p \leq 0.001$) (Fig. 3). Seroconversion
352 for neutralising antibodies to SARS-CoV-2 occurred in 75 (24.4%, 95% CI: 19.7; 29.5) of 308
353 participants on Day 14. No increase in neutralising antibody from baseline was observed in the
354 Placebo group. On Day 28, seroconversion for neutralising antibodies to SARS-CoV-2 occurred in
355 183 (59.0%, 95% CI: 53.3; 64.6) of 320 participants; notably, greater proportions were observed in

356 the Ad5-nCoV group on days 14 and 28 compared with the Placebo group ($p < 0.001$). At Month 6,
357 149 (48.9%, 95% CI 43.1; 54.6) of 305 participants had a 4-fold or greater increase of neutralising
358 antibodies compared with the Placebo group (32/93 [34.4%, 95% CI: 24.9; 45.0; $p = 0.012$]).

359 **Fig. 3.** Seroconversion rates of the neutralising antibodies against SARS-CoV-2 and the
360 seroconversion rate against the RBD and SARS-CoV-2 S protein on Day 0, Day 14, Day 28 and
361 Month 6 after vaccination. The seroconversion rates with 95% CI are shown for serum antibodies
362 against Ad5 (ADENOVAB), SARS-CoV-2 neutralising antibodies (SAR2NAB), RBD (SAR2RBD)
363 and S protein (SAR2S) (***, $p < 0.001$; *, $p < 0.05$). Ad5, adenovirus type-5; CI, confidence interval;
364 RBD, receptor binding domain; S, spike; SARS-CoV-2, severe acute respiratory syndrome
365 coronavirus 2.

366 Almost all participants had neutralising antibodies against the Ad5 vector at baseline: 317/372
367 (85.2%) participants who received Ad5-nCoV and 106/124 (85.5%) who received placebo. For most
368 participants, the antibody titre to Ad5 was low ($\leq 1:200$) (Fig. 4); very few participants had high
369 ($> 1:200$) levels of pre-existing antibodies to Ad5 (7/424, 1.7%). Geometric mean anti-Ad5 antibody
370 titre in participants with low pre-existing anti-Ad5 antibodies increased from 11.3 at baseline
371 ($n = 317$) to 36.5 at Day 28 ($n = 353$), which then increased further to 48.3 ($n = 355$) at Month 6.
372 Corresponding values for the very few participants with pre-existing immunity to Ad5 $> 1:200$
373 showed an increase from 320.0 at baseline ($n = 6$) to 359.2 at Day 28 ($n = 6$) and a further increase to
374 557.2 at Month 6 ($n = 6$). The GMT of neutralising antibodies against the Ad5 vector in all
375 participants who received Ad5-nCoV was 11.28 on Day 0 (95% CI: 9.95; 12.78), 36.48 on Day 28
376 (95% CI: 30.72; 43.30) and 48.34 at Month 6 (95% CI: 40.25; 58.05), with significant levels of
377 neutralising antibodies against Ad5 present at Day 28 and Month 6, compared with the Placebo
378 group ($p \leq 0.001$).

379 **Fig. 4.** Titre distribution of anti-Ad5 antibodies on Day 0, Day 28 and Month 6 after vaccination in
380 those from either the Ad5-nCoV or Placebo groups.

381 The effect of pre-existing immunity to Ad5 on the immunological responses to the vaccine was
382 studied. As presented in Fig. 5, the increase of GMTs to anti-RBD antibodies after vaccination in the
383 Ad5-nCoV group was comparable between patients with high ($>1:200$) and low ($\leq 1:200$) baseline
384 titres of antibodies to Ad5 up to Day 28, although this observation may be attributed to the small
385 number of patients with pre-existing high Ad5 titres ($n=7$).

386 **Fig. 5.** Antibody responses to SARS-CoV-2 vaccine in those with pre-existing immunity to Ad5.
387 Geometric mean titre (GMT) of titres in response to anti-Ad5 antibody (ADENOVAB), anti-RBD
388 (SAR2RBD) and S protein (SAR2S) antibodies as well as neutralising SARS-CoV-2 antibodies
389 (SAR2NAB) on Day 0, Day 14, Day 28 and Month 6 after vaccination. Volunteers are divided into
390 seven (from 1:5 to 1:320) cohorts based on their pre-existing anti-Ad5 antibody levels. Ad5,
391 adenovirus type-5; CI, confidence interval; RBD, receptor binding domain; S, spike; SARS-CoV 2,
392 severe acute respiratory syndrome coronavirus 2.

393 Pearson's correlation coefficients between baseline GMTs to Ad5, GMTs to RBD and S protein
394 antibodies as well as neutralising SARS-CoV-2 antibodies were calculated. There was a negative
395 correlation of -0.36 between baseline GMT to Ad5 and GMT to RBD on Day 14 that weakened
396 to -0.05 at 6 months post-vaccination. The correlations between baseline GMT and GMTs to S
397 protein and neutralising SARS-CoV-2 antibodies decreased by Month 6 (Fig. 6). The decrease in
398 correlation was less pronounced between GMTs to RBD, indicating that the relationship between
399 levels of baseline Ad5 GMTs to the COVID-19 humoral immune response weakens over time
400 following vaccination.

401 **Fig. 6.** Pearson's correlation coefficient between GMTs versus anti-Ad5 antibodies (ADENOVAB)
402 in response to anti-RBD (SAR2RBD) and S protein (SAR2S) antibodies as well as neutralising
403 SARS-CoV-2 antibodies (SAR2NAB) on Day 0, Day 14, Day 28 and Month 6 after vaccination. The
404 correlation coefficients with 95% CI are shown. Ad5, adenovirus type-5; CI, confidence interval;
405 RBD, receptor binding domain; S, spike; SARS-CoV 2, severe acute respiratory syndrome
406 coronavirus 2.

407 The effect of the vaccination on cellular immune responses was studied in a subgroup of 69
408 participants recruited by Moscow research centres (Ad5-nCoV group, n=50 volunteers; placebo
409 group, n=19). The presence of SARS-CoV-2 specific CD8⁺ and CD4⁺ T cells in venous blood
410 samples was assessed by counting the number of spot-forming cells (SFCs; i.e., IFN- γ secreting
411 cells) in an ELISpot assay in which isolated PBMCs were stimulated with either full-length S protein
412 or a pool of overlapping peptides covering the S protein (i.e., peptide pool). The most pronounced
413 response occurred on Day 14 after the Ad5-nCoV vaccination in which the median number of SFCs
414 was 32.8 (Quartile [Q]1: 19.0, Q3: 78.9) when stimulated with the peptide pool and 32.2 (Q1: 16.0,
415 Q3: 99.9) when stimulated with full-length S protein (Fig. 7A and 7B, respectively). For cells
416 stimulated with the peptide pool, the median number of SFCs decreased to 5.5 (Q1: 1.5, Q3: 12.2) on
417 Day 28 and further still to 1.5 (Q1: 0, Q3: 8.5) at Month 6. When stimulated with full-length S
418 protein, the number of SFCs increased to 4.5 (Q1: 3.0, Q3: 12.5) on Day 28 and 5.5 (Q1: 0.75, Q3:
419 13.8) by 6 months post-vaccination.

420 **Fig. 7.** Assessing the cellular immune response to SARS-CoV 2 vaccine using an enzyme-linked
421 immunospot (ELISpot) assay. Peripheral blood mononuclear cells (PBMCs) were isolated from
422 blood samples taken from participants from either the Placebo or Ad5-nCoV group. PBMCs isolated
423 on Day 0, Day 14, Day 28 and Month 6 after vaccination were stimulated with (A) a pool of peptides
424 that span the S protein (i.e., peptide pool) or (B) the full-length S protein. The response of T cells

425 was determined by counting IFN- γ -positive spot-forming cells (SFCs). Spots were quantified via an
426 automated digital image. The median with quartiles is the plotted, the dotted line indicates the
427 positivity threshold (***, $p < 0.001$; **, $p < 0.01$). Ad5, adenovirus type-5; S, spike; SARS-CoV-2,
428 severe acute respiratory syndrome coronavirus 2.

429 Compared with the response observed in the Placebo group, those in the Ad5-nCoV group displayed
430 significantly higher numbers of IFN- γ -positive T cells, regardless of how the cells were stimulated,
431 on Days 14 ($p < 0.001$) and 28 ($p < 0.01$). However, 6 months post-vaccination, the differences
432 between the groups were not statistically significant when cells were stimulated with the full-length
433 S protein ($p = 0.6$) or with the peptide pool ($p = 1.0$).

434 The percentage of participants who had an IFN- γ response above the threshold following stimulation
435 with the peptide pool on Day 14 in the Ad5-nCoV group was 91.7% (95% CI: 80.4; 96.7), whereas
436 no participants were positive in the Placebo group. During the follow-up period, the response rate
437 decreased for those in the Ad5-nCoV group and the percentage of patients that displayed an IFN- γ
438 response on Day 28 was 37.2% (95% CI: 24.4; 52.1), whereas no participants were positive in the
439 Placebo group. At Month 6, the percentage of patients displayed an IFN- γ response was 21.2% and
440 12.5% in the Ad5-nCoV and Placebo groups, respectively. The trend of an IFN- γ response for cells
441 stimulated with full-length S protein was similar to the trend observed when cells were stimulated
442 with the peptide pool. The percentage of participants who displayed an IFN- γ response following
443 stimulation with full-length S protein in the Ad5-nCoV group on Day 14 was 83.3% (95% CI: 70.4;
444 91.3), whereas no participants were positive in the Placebo group. During the follow-up period, the
445 response rate markedly decreased for those in the Ad5-nCoV group and the percentage of patients
446 that displayed an IFN- γ response on Day 28 was 30.2% (95% CI: 18.6; 45.1), whereas there was one
447 participant who had an IFN- γ response in the Placebo group. At Month 6, 31% of patients (95% CI:

448 20.4; 46.2) displayed an IFN- γ response that was comparable to 25% of patients in the Placebo group
449 following stimulation with the full-length S protein.

450 Of note, 31 of the participants were confirmed to have COVID-19 within 14 days post-vaccination.
451 Thirteen participants were from the Placebo group (13/31 [11.32%]), whereas 18/31 (4.97%)
452 participants were from the Ad5-nCov group ($p=0.023$). Cases of severe COVID-19 (with the
453 exception of COVID-19 cases that occurred during the first 14 days post-vaccination) were
454 registered in only 2 (1.7%) participants, both of whom were from the Placebo group. Both of these
455 severe COVID-19 cases required hospitalization. No deaths from COVID-19 were registered.

456 **Safety evaluation**

457 *Systemic (general) immunisation reactions*

458 A total of 113 (22.8%) of the 372 participants who received the Ad5-nCoV vaccine reported
459 systemic reactions (Table 2). The incidence of systemic reactions was significantly higher than in the
460 Placebo group, where 13 (10.5%) of the 124 participants reported systemic reactions.

461 **Table 2. Summary of adverse events (AEs) by safety analysis set.**

	Ad5-nCoV N = 372	Placebo N = 124	Total N = 496
Systemic (general) immunisation reactions	100 (26.9%)/162	13 (10.5%)/20	113 (22.8%)/182
Grade 1	78 (21.0%)/131	10 (8.1%)/16	88 (17.7%)/147
Grade 2	17 (4.6%)/26	3 (2.4%)/4	20 (4.0%)/30
Grade 3	5 (1.3%)	0	5 (1.0%)
Local immunisation reactions	106 (28.5%)/180	2 (1.6%)/4	108 (21.8%)/184
Grade 1	91 (24.5%)/154	2 (1.6%)/4	93 (18.8%)/158
Grade 2	15 (4.0%)/26	0	15 (3.0%)/26
Grade 3	0	0	0
AEs (except for immunisation reactions)	152 (40.9%)/365	38 (30.6%)/75	190 (38.3%)/440
AEs related to vaccination	130 (34.9%)/280	25 (20.2%)/43	155 (31.3%)/323
Grade 1	106 (28.5%)/246	20 (16.1%)/36	126 (25.4%)/282
Grade 2	21 (5.6%)/30	5 (4.0%)/7	26 (5.2%)/37
Grade 3	3 (0.8%)/4	0	3 (0.6%)/4
AEs related to vaccination and registered during the first 7 days after vaccination	123 (33.1%)/244	25 (20.2%)/42	148 (29.8%)/286
Serious AEs	1 (0.3%)/1	5 (4.0%)/5	6(1.2%)/6
Death	0	0	0
Early discontinuation due to AE	0	0	0

462 Data presented as the number of participants with adverse events per category (%) / number of AE records.

463

464 The most commonly reported reactions in the Ad5-nCoV group included increase in body
465 temperature (20.2%), headache (5.9%), fatigue (5.4%), myalgia (4.8%) and arthralgia (1.9%; S1
466 Table). For most participants, general immunisation reactions were mild (Grade 1, 21.0%). Moderate
467 (Grade 2) reactions occurred in 4.6% of participants and included increase in body temperature,
468 headache, myalgia, arthralgia, and fatigue. Severe (Grade 3) reactions, including an increase in body
469 temperature (39.0–40.0 °C), occurred in 4 participants, and myalgia occurred in only 1 participant
470 (Table 2 and S2 Table).

471 In the Placebo group, reactions included increase in body temperature (6.5%), headache (4.8%),
472 fatigue (5.4%) and diarrhoea (0.8%). These AEs were mild or moderate; no severe reactions were
473 reported (Table 2, S1 Table and S2 Table).

474 There were no fatal outcomes. During the first 7 days after vaccination, a total of six serious AEs
475 (SAEs) were reported (Table 2): one SAE in 1 (0.3%) participant from the Ad5-nCoV group and five
476 SAEs in 5 (4.0%) participants from the Placebo group. Of note, two of the participants from the
477 Placebo group were hospitalised due to COVID-19. For the only SAE event experienced by a
478 participant from the Ad5-nCoV group, the event was found to have no connection with the study
479 drug. The SAEs are described in S3 Table.

480 *Injection site reactions*

481 Injection site reactions occurred in 106 participants (28.5%) who received the Ad5-nCoV vaccine.
482 By comparison, only 2 participants in the Placebo group (1.6%) experienced an injection site
483 reaction including swelling and pain or induration (S4 Table), all of which were Grade 1 in severity
484 (S5 Table). The most common reactions included pain (16.9%), erythema (14.8%) and induration at
485 the injection site (4.8%) (S4 Table). As listed in S5 Table, for most participants, local injection site
486 reactions were mild (24.5%). Fifteen participants (4.0%) who received the Ad5-nCoV vaccine had a
487 moderate reaction that included pain, erythema, swelling or induration at the injection site. No severe
488 reactions were reported.

489 *Other adverse events (excluding immunisation reactions)*

490 A total of 190 participants (38.3%) reported other AEs during the 6 months after vaccination;
491 152/365 (40.9%) participants from the Ad5-nCoV group and 38/75 (3.6%) participants from the
492 Placebo group. As listed in Table 2, these AEs were assessed by the investigators as related to the

493 vaccine (Ad5-nCoV: 34.9%; Placebo: 20.2%). The majority of vaccine-related AEs were reported
494 during the first 7 days after vaccination (Ad5-nCoV: 33.1%; Placebo: 20.2%). In both groups, the
495 most common AEs were out-of-range laboratory measurements: 34.4% reported by participants in
496 the Ad5-nCoV group and 16.9% from the Placebo group. The most pronounced differences in AE
497 incidence in the Ad5-nCoV group compared with the Placebo group were: increases in C-reactive
498 protein (17.6% vs. 2.4%), monocytes (4.0% vs. 0%) and aspartate aminotransferase (1.6% vs. 1.6%)
499 as well as a decrease in neutrophils (6.2% vs 2.4%) (S6 Table).

500 For most participants, AEs were mild, reported in 28.5% of the Ad5-nCoV group and 16.1% of the
501 Placebo group. Moderate events were registered in 5.6% of participants who received the Ad5-nCoV
502 vaccine and 4.0% who received the placebo. By comparison, SAEs occurred in 0.8% of participants
503 in the Ad5-nCoV group, but none in the Placebo group; these included increases in C-reactive
504 protein (0.5%) and blood fibrinogen levels (0.5%).

505 For most participants, general and injection site reactions and AEs resolved within 7 days after
506 vaccination.

507 Results of the analysis of laboratory parameters demonstrated a trend towards an increase in C-
508 reactive protein levels, an increase in the red cell sedimentation rate, an increase in the mean
509 percentage of monocytes, and a decrease in the mean percentage of neutrophils after administration
510 of Ad5-nCoV. The changes in the examined laboratory parameters were pronounced the day after
511 vaccination, but had largely resolved by Day 28.

512 The proportion of participants in the Ad5-nCoV group with elevated IgE at Day 28 showed no
513 changes from screening: 73/372 (19.6%) to 76/365 (20.8%).

514 **DISCUSSION**

515 In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial including 500 adult
516 participants aged 18–85 years (mean age: 41.2 years), the immunogenicity, efficacy and safety of the
517 Ad5-nCoV COVID-19 vaccine was assessed up to 6 months after vaccination. Both study groups
518 (Ad5-nCoV and placebo) had similar baseline characteristics. A single immunisation with the Ad5-
519 nCoV vaccine led to a marked immune response. The primary endpoint (seroconversion rate of anti-
520 RBD antibodies on Day 28 after vaccination) and all secondary endpoints on Day 28 after
521 vaccination showed statistically significant superiority of the Ad5-nCoV vaccine compared with
522 placebo ($p < 0.001$).

523 The seroconversion rate of antibodies against the RBD of the SARS-CoV-2 S protein (78.5%) and of
524 neutralising antibodies against SARS-CoV-2 (59%) on Day 28 were similar to the results obtained
525 during the interim analysis of a phase 2 clinical study conducted in China. The seroconversion rate of
526 anti-RBD antibodies in the Ad5-nCoV group was 97% (95% CI: 92; 99), and the seroconversion rate
527 of neutralising antibodies against live SARS-CoV-2 was 47% (95% CI: 39; 56) [9].

528 The GMTs of anti-RBD, S protein-specific antibodies and neutralizing SARS-CoV-2 antibodies
529 increased significantly at Month 6 post-vaccination in the Placebo group, not by Day 14 or Day 28.
530 We theorized two possible explanations. First, some individuals might have been asymptomatic
531 while infected with COVID-19, or COVID-19-positive patients did not report their symptoms to the
532 study's physicians. Second, individuals in the Placebo group might have taken a commercially
533 available antibody test that was widely available in Russia and decided to receive another
534 vaccination after observing their low antibody titres, thereby confounding their treatment status. Two
535 participants were excluded from the PPS for this reason, but many more could have been unreported.

536 Adenovirus exposure is common. Pre-existing anti-Ad5 immunity may affect the immunogenicity of
537 Ad5-based vaccines, and as a result, their efficacy against COVID-19. However, the proportion of
538 individuals with high anti-Ad5 titres in a population varies across regions [17–19] and it is unclear to
539 what extent previous exposure influences existing titres and the speed of their decline. A titre of
540 1:200 was selected as the cut-off point for low and high anti-Ad5 antibodies during the phase 1 and 2
541 studies in China. Those with low baseline anti-Ad5 titres ($\leq 1:200$) had RBD-specific antibody and
542 neutralising antibody levels roughly twice as high as those with high baseline anti-Ad5 titres
543 ($> 1:200$) [9, 10]. Our data analysis used a cut-off of 1:200 in line with the Chinese studies, but given
544 the variable levels of anti-Ad5 titres around the world, a limit of 1:200 may not necessarily be
545 appropriate in all regions. The selection of an appropriate cut-off point in the current study was
546 hampered by a lack of published data on anti-Ad5 levels in the Russian population. Among the
547 Russian participants, those with baseline levels of anti-Ad5 antibodies showed a very small group of
548 7 (1.4%) participants with titres of approximately 1:320 (Fig. 4). All of them were in the subgroup of
549 participants aged 18 to 45 years.

550 In this study, we uncovered the response of pre-existing immunity to Ad5 and showed how it affects
551 subsequent humoral immune responses as well as the longevity of immunity to COVID-19. In
552 participants vaccinated with Ad5-nCoV, there was no difference in humoral immunity to COVID-19
553 between those with baseline Ad5 titres above or below the cut-off of 1:200. However using a cut-off
554 of 1:5, we showed that those with baseline Ad5 titres of 1:5 displayed a greater amount of GMTs to
555 anti-RBD and S protein antibodies as well as neutralising SARS-CoV-2 antibodies than those with a
556 higher baseline ratio of Ad5 titres (Fig. 5). The relationship between the levels of baseline Ad5
557 GMTs to the respective antigen tends to weaken over time following vaccination (Fig. 6). Studies
558 with longer follow-up periods would help to clarify the longevity of the immune response in those

559 vaccinated with Ad5-nCoV. Moreover, studies with a larger dataset would help to determine if pre-
560 existing immunity to Ad5 correlates to protection efficacy.

561 Our study provides data on the incidence of anti-Ad5 immunity in the Russian population, admittedly
562 in a relatively small sample size. Almost all participants had pre-existing neutralising antibodies to
563 Ad5, although levels were generally very low. No such data were available before this study, and
564 only limited and highly variable data are available for the level of Ad5 immunity in Europe.

565 The results from this study demonstrate that the experimental Ad5-nCoV vaccine has a good safety
566 profile comparable with the findings of preceding clinical trials in healthy adults. Most post-
567 vaccination AEs were mild or moderate in severity. Although the proportions of participants who
568 reported adverse reactions such as an increase in body temperature, headache, and pain at the
569 injection site were higher in those that received the Ad5-nCoV vaccine, adverse reactions within
570 28 days were generally mild to moderate and the majority resolved within 7 days after vaccination.
571 All Grade 3 AEs occurred among participants from the Ad5-nCoV group and were similar to
572 commonly reported AEs after other types of immunisation.

573 There are currently multiple recombinant Ad-vectored COVID-19 candidate vaccines in
574 development [4–7, 9, 10, 20, 21]. The most relevant comparator vaccine in terms of the practicalities
575 of storage, transport and administration is the Ad26.COV2.S vaccine [22]. Like the Ad5-nCoV
576 vaccine, it can be administered as a single dose, stored in a standard refrigerator without the need for
577 ultra-low temperature freezing and is stable at room temperature prior to administration. An interim
578 analysis of Ad26.COV2.S showed that vaccine-induced neutralising antibodies against wild-type
579 virus were detected in 95% or more of participants on day 29 after dosing. Our qualitative analysis
580 used a similar definition of seroconversion to that used to assess the Ad26.COV2.S vaccine [22]; as
581 well as including participants who seroconverted from below the LLOQ of the assay at baseline to

582 detectable antibodies at Day 28, it included those with a 4-fold or greater increase in antibody titre
583 over the same period. The Ad5-nCoV vaccine provided a similar antibody response to
584 Ad26.COV2.S: 95.9% of subjects developed antibodies to the S protein and 92.5% to the smaller
585 anti-RBD region by Day 28.

586 This study has several limitations. First, the participants included in this study were all white,
587 although conversely, this also provided the first data in a non-Chinese, European population. Second,
588 this trial did not include children or pregnant women, and there were only a small number of older
589 adults (35 were ≥ 60 years in the Ad5-nCoV group). An ideal candidate vaccine for COVID-19
590 should cover vulnerable populations of all ages. Anti-S protein-specific antibodies have been
591 reported to decline rapidly in individuals who have recovered from COVID-19, especially those who
592 were asymptomatic or had mild symptoms [23]. Third, the sample size was relatively small and some
593 of the calculated 95% CIs were wide. Finally, virus mutation, an emerging problem, may reduce the
594 effectiveness of current vaccines [24]. It is not known whether participants of this study were
595 exposed to any COVID-19 variants. Further study is underway to determine neutralising antibodies
596 to the widely circulating variants following vaccination with Ad5-nCoV, which include but are not
597 limited to the Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) variants.

598 **Conclusions**

599 Analysis of data from this phase 3 trial demonstrated the immunogenicity and safety of this Ad5-
600 vector based COVID-19 vaccine. More data are required to determine whether this vaccine reduces
601 infections and transmission. Overall, this stable, single-dose vaccine could contribute to the global
602 fight against the evolving SARS-CoV-2 virus.

603 **DECLARATIONS**

604 **Acknowledgements**

605 Medical writing support was provided by Dr Justin Cook, Dr Antria Siakalli and Dr Caitlin Tolbert
606 of Niche Science and Technology Ltd, Richmond-upon-Thames, Surrey, UK; this was paid for by
607 NPO Petrovax Pharm LLC, 1, Moscow region, Russian Federation.

608 **Supporting Information**

609 S1 Protocol. Study Protocol.

610 S1 Checklist. CONSORT Checklist.

611 S1 Table. Systemic (general) post-vaccination reactions (Safety population).

612 S2 Table. Systemic (general) post-vaccination reactions by severity (Safety population).

613 S3 Table. Summary of all severe adverse events that led to hospitalisation or prolonged
614 hospitalisation.

615 S4 Table. Local post-vaccination reactions (Safety population).

616 S5 Table. Local post-vaccination reactions by severity (Safety population).

617 S6 Table. Other adverse events unrelated to vaccination reactions (Safety population).

618 **Author Contributions**

619 **Conceptualization:** Vitalina Dzutseva, Grigory A. Efimov, Mikhail Tsyferov, Anton Tikhonov,
620 Andrei Afanasiev.

621 **Data Curation:** Dmitry Lioznov, Irina Amosova.

622 **Formal Analysis:** Dmitry Zubkov.

623 **Investigation:** Savely A. Sheetikov, Ksenia V. Zornikova, Yana Serdyuk, Grigory A. Efimov,
624 Dmitry Lioznov, Irina Amosova.

625 **Methodology:** Grigory A. Efimov, Dmitry Lioznov, Tao Zhu, Luis Barreto, Vitalina Dzutseva.

626 **Project Administration:** Vitalina Dzutseva, Mikhail Khmelevskii.

627 **Resources:** Savely A. Sheetikov, Ksenia V. Zornikova, Yana Serdyuk, Grigory A. Efimov, Vitalina
628 Dzutseva.

629 **Supervision:** Grigory A. Efimov, Vitalina Dzutseva, Dmitry Lioznov.

630 **Validation:** Irina Amosova, Grigory A. Efimov, Dmitry Lioznov.

631 **Visualisation:** Dmitry Zubkov, Anton Tikhonov.

632 **Writing – Original Draft Preparation:** Anton Tikhonov, Nadezhda Khomyakova, Andrei
633 Afanasiev.

634 **Writing – Review and Editing:** Anton Tikhonov, Nadezhda Khomyakova, Dmitry Lioznov,
635 Grigory A. Efimov, Mikhail Tsyferov, Irina Amosova, Savely A. Sheetikov, Ksenia V. Zornikova,
636 Yana Serdyuk, Dmitry Zubkov, Andrei Afanasiev, Tao Zhu, Luis Barreto.

637 **Funding and role of study sponsor**

638 The study was designed, funded, and managed by NPO Petrovax Pharm LLC (Moscow, Russian
639 Federation). NPO Petrovax Pharm LLC in partnership with CanSino Biologics, Inc. (Tianjin, China)

640 are funding and managing the clinical development of the Ad5-nCoV vaccine in the Russian
641 Federation.

642 **Conflicts of interest/competing interests**

643 All authors have read the journal's policy and the authors of this manuscript have the following
644 competing interests: MT, MK, DZ, AA, NK, AT and VD are employees of NPO Petrovax Pharm
645 LLC. TZ and LB are employees of CanSino Biologics, Inc. IA, SS, KZ and YS have received
646 funding from NPO Petrovax Pharm LLC for consultation services. DL and GE have received
647 personal fees from NPO Petrovax Pharm LLC for consultation services.

648 **Availability of data and material**

649 The authors confirm that the data supporting the findings of this study are available within the article.

650 **Transparency declaration**

651 The corresponding author and guarantor (Vitalina Dzutseva) affirms that this manuscript is an
652 honest, accurate, and transparent account of the study being reported; that no important aspects of the
653 study have been omitted; and that any discrepancies from the study as planned have been explained.

654 **REFERENCES**

- 655 1. Martini M, Gazzaniga V, Bragazzi NL, Bardberis I. The Spanish Influenza Pandemic: a
656 lesson from history 100 years after 1918. *J Prev Med Hyg.* 2019;60(1):E64-E67. doi: 10.15167/2421-
657 4248/jpmh2019.60.1.1205.
- 658 2. Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al.
659 Quarantine alone or in combination with other public health measures to control COVID-19: a rapid
660 review. *Cochrane Database Syst Rev.* 2020;4(4):CD013574. doi: 10.1002/14651858.Cd013574.
- 661 3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
662 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615. doi:
663 10.1056/NEJMoa2034577.
- 664 4. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and
665 efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of
666 four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet.* 2021;397(10269):99-
667 111. doi: 10.1016/S0140-6736(20)32661-1.
- 668 5. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety
669 of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med.* 2020;384(5):403-416. doi:
670 10.1056/NEJMoa2035389.
- 671 6. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV,
672 Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous
673 prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies
674 from Russia. *Lancet.* 2020;396(10255):887-897. doi:10.1016/s0140-6736(20)31866-3.

- 675 7. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. *Virus Res.*
676 2020;288:198114. doi: 10.1016/j.virusres.2020.198114.
- 677 8. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, et al. Potent neutralization of
678 severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks
679 receptor association. *Proc Natl Acad Sci U S A.* 2004;101:2536-2541.
- 680 9. Zhu F, Guan X, Li Y, Huang J, Jiang T, Hou L, et al. Immunogenicity and safety of a
681 recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older:
682 a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet.* 2020;396: 479–488. doi:
683 10.1016/S0140-6736(20)31605-6.
- 684 10. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and
685 immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,
686 open-label, non-randomised, first-in-human trial. *Lancet.* 2020;395(10240):1845-1854. doi:
687 10.1016/S0140-6736(20)31208-3.
- 688 11. Food and Drug Administration (FDA). Center for Biologics Evaluation and Research.
689 Development and Licensure of Vaccines to Prevent COVID-19. 2020. Available from:
690 <https://www.fda.gov/media/139638/download>
- 691 12. European Medicines Agency (EMA). Guideline on clinical evaluation of vaccines. 2018.
692 Available from: [https://www.who.int/publications/i/item/an-international-randomised-trial-of-](https://www.who.int/publications/i/item/an-international-randomised-trial-of-candidate-vaccines-against-covid-19)
693 [candidate-vaccines-against-covid-19](https://www.who.int/publications/i/item/an-international-randomised-trial-of-candidate-vaccines-against-covid-19)
- 694 13. Rules for Conducting Studies of Biological Medicinal Products of the Eurasian Economic
695 Union. 2016. Available from: https://docs.eaeunion.org/docs/ru-ru/01411954/cncd_21112016_89

- 696 14. Guidelines for Conducting Clinical Studies of Medicinal Products (Immunobiologicals).
697 Part two. 2012: 212. Available from: [https://www.thelancet.com/action/showPdf?pii=S0140-](https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931605-6)
698 [6736%2820%2931605-6](https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931605-6)
- 699 15. Clinicaltrials.gov. Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus
700 Type 5 Vector) Against COVID-19. 2020. Available from:
701 <https://clinicaltrials.gov/ct2/show/NCT04540419?term=prometheus&cond=Covid19&cntry=RU&dr>
702 [aw=2&rank=1](https://clinicaltrials.gov/ct2/show/NCT04540419?term=prometheus&cond=Covid19&cntry=RU&dr)
- 703 16. Shomuradova AS, Vagida MS, Sheetikov SA, Zornikova KV, Kiryukhin D, Titov A, et al.
704 SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell
705 Receptors. *Immunity*. 2020;53(6):1245-1257.e5. doi: 10.1016/j.immuni.2020.11.004.
- 706 17. Yu B, Zhou Y, Wu H, Wang Z, Zhan Y, Feng X, et al. Seroprevalence of neutralizing
707 antibodies to human adenovirus type 5 in healthy adults in China. *J Med Virol*. 2012;84(9):1408-
708 1414. doi: 10.1002/jmv.23325.
- 709 18. Pilankatta R, Chawla T, Khanna N, Swaminathan S. The prevalence of antibodies to
710 adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.
711 *J Med Virol*. 2010;82(3):407-414. doi: 10.1002/jmv.21721.
- 712 19. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. International
713 seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.
714 *Vaccine*. 2011;29(32):5203-5209. doi: 10.1016/j.vaccine.2011.05.025.
- 715 20. Tan Y. Covid: what do we know about China's coronavirus vaccines? *News: BBC*. 2021.
716 Available from: <https://www.bbc.co.uk/news/world-asia-china-55212787>

- 717 21. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. *Lancet*.
718 2021;397(10275):642-643. doi: 10.1016/S0140-6736(21)00191-4.
- 719 22. Sadoff J, Le Gars M, Shukarev, Heerwegh D, Truyers C, de Groot AM, et al. Interim
720 Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. *New Engl J Med*.
721 2021;384(19):1824-1835. doi: 10.1056/NEJMoa2034201.
- 722 23. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological
723 assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020;26(8):1200-1204. doi:
724 10.1038/s41591-020-0965-6.
- 725 24. Mancini DP, Kuchler H, Pilling D, Cookson C, Cotterill J. Oxford/AstraZeneca jab fails to
726 prevent mild and moderate Covid from S African strain, study shows. *Financial Times*. 2021.
727 Available from: <https://www.ft.com/content/e9bbd4fe-e6bf-4383-bfd3-be64140a3f36>

783 - Screened
500 - Randomised

374 - Allocated to receive Ad5-nCoV
1 - Withdrawal of informed consent
1 - Screening failure (randomised by mistake)

372 - FAS for safety
analysis

372 - Received Ad5-nCoV
1 - Violation of selection criteria

371 - FAS for immunogenicity analysis

3 - Registered COVID-19 cases before Day 14
1 - Prohibited therapy
11 - Visit 4 (out of window)
22 - Visit 5 (out of window)
2 - No initial primary immunogenicity variables
8 - Data missing from Visits 4, 5 and post-
vaccination

324 - PPS for immunogenicity analysis

1 - Violation of selection criteria
3 - Registered COVID-19 cases before Day 14
5 - Data missing post-vaccination

363 - FAS for efficacy analysis

1 - Prohibited therapy
1 - Unblinded with AE

361 - PPS for efficacy analysis

126 - Allocated to receive Placebo
2 - Screening failure (randomised by mistake)

124 - FAS for safety
analysis

124 - Received placebo

124 - FAS for immunogenicity analysis


1 - Registered COVID-19 asymptomatic case
8 - Visit 4 (out of window)
14 - Visit 5 (out of window)
6 - Data missing from Visits 4, 5 and post-
vaccination


95 - PPS for immunogenicity analysis

1 - Registered COVID-19 asymptomatic case
3 - Data missing post-vaccination







120 - FAS for efficacy analysis


120 - PPS for efficacy analysis







medRxiv preprint doi: <https://doi.org/10.1101/2022.03.01.22271507>; this version posted March 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.







A**B**